Saturday 17 October 2026
Export MBIO’s income statement to Excel — free account
Mustang Bio, Inc.
MBIO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 15.8% and free cash flow grew 27.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
0.38
0.01
−2.56%
Follow MBIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(418.83%) | (67.93%) | (44.62%) | (58.12%) | |
| (17.59%) | (14.28%) | (17.29%) | (21.17%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(23.54%) | (19.85%) | (31.13%) | (39.42%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.71) | (0.84) | (0.73) | (0.67) | |
Free Cash Flow |
(4.41) | (4.10) | (4.88) | (4.51) | |
Capital Expenditures |
1.14 | 1.17 | — | — | |
| Other line items | |||||
Cash ROIC |
(15.33%) | (15.30%) | (19.65%) | (19.88%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
2.37 | 2.74 | 1.79 | 1.49 | |
Depreciation/Fixed assets |
0.00 | 0.00 | — | — | |
Capex/Depreciation |
9.78 | 28.41 | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.89) | (1.07) | (0.73) | (0.67) | |
Capex per Share |
0.18 | 0.24 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates